Trial · NCT07469956
Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer
NCT07469956, Phase 2, Not yet recruiting, Sun Yat-sen University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer. Trials, record NCT07469956. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07469956
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer
- NCT number
- NCT07469956
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 30 participants, estimated
- Lead sponsor
- Sun Yat-sen University
- Conditions
- Pancreatic Cancer Resectable
- Interventions
- Surufatinib, Toripalimab, mFOLFIRINOX
- First posted
- 2026-03-13
- Last updated
- 2026-03-13
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 12-month Event Free Survival Rate | From enrollment to the end of observation at 12 months | Event-free survival (EFS) is defined as the time from enrollment to the first occurrence of any of the following events, including (1) disease progression according to RECIST criteria, (2) undergoing R2 resection surgery, (3) disease recurrence after surgery, or (4) death from any cause. The 12-month EFS rate is defined as the proportion of patients among the total enrolled who have not experienced any of the above predefined events within 12 months from enrollment. |
| Secondary | R0 Resection Rate | From enrollment to the end of treatment for up to 16 weeks | The proportion of patients whose postoperative pathological evaluation shows no residual tumor cells at all surgical margins (R0) among all patients who underwent surgery after receiving neoadjuvant therapy. |
| Secondary | Objective Response Rate | From enrollment to the end of treatment for up to 16 weeks | Refers to the proportion of patients whose tumors shrink by a certain amount and maintain it for a certain period of time, including cases of CR and PR. The objective response rate is evaluated using the RECIST 1.1. Subjects must have measurable tumor lesions at enrollment, and the efficacy evaluation criteria according to RECIST 1.1 are classified as complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). |
| Secondary | Disease Control Rate | From enrollment to the end of treatment for up to 16 weeks | Refers to the percentage of patients with complete response, partial response, and stable disease maintained for more than 4 weeks among those evaluable for efficacy. |
| Secondary | Recurrence Free Survival | From the date of surgery at week 18 to the recurrence of the tumor or death for up to 96 weeks. | Recurrence-free survival (RFS) refers to the time interval from the date of surgery following neoadjuvant therapy to the recurrence of the tumor (including local/regional recurrence or distant metastasis) or death from any cause. |
| Secondary | Overall Survival | From enrollment to the date of death from any cause for up to 96 weeks. | Overall survival (OS) refers to the time from enrollment to the date of death from any cause. |
| Secondary | AEs | From enrollment to 30 days after the end of treatment at 16 weeks | Collect adverse events (AEs) from enrollment to 30 days after the end of treatment, and grade the AEs according to CTCAE 5.0. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07469956
GET https://conductscience.org/api/trials/v1/NCT07469956/registered